Evidence map›Paper›PMID 38969985›Full record

ArticleClinical proteomics2024

A single-sample workflow for joint metabolomic and proteomic analysis of clinical specimens.

Hagen M Gegner, Thomas Naake, Karim Aljakouch, Aurelien Dugourd, Georg Kliewer, Torsten Müller, Dustin Schilling, Marc A Schneider, Nina Kunze-Rohrbach, Thomas G P Grünewald and 5 more

Abstract read
In one paragraph

Article in Clinical proteomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Deep Proteome Profiling of Primary Skin Fibroblasts.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hagen M GegnerCentre for Organismal Studies (COS), Metabolomics Core Technology Platform, Heidelberg University, Im Neuenheimer Feld 360, 69120, Heidelberg, Germany.
Thomas NaakeGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstr. 1, 69117, Heidelberg, Germany.
Karim AljakouchFaculty of Medicine, Heidelberg University, 69120, Heidelberg, Germany.
Aurelien DugourdInstitute for Computational Biomedicine, Bioquant, Faculty of Medicine, Heidelberg University and Heidelberg University Hospital, Im Neuenheimer Feld 130, 69120, Heidelberg, Germany.
Georg KliewerFaculty of Medicine, Heidelberg University, 69120, Heidelberg, Germany.
Torsten MüllerFaculty of Medicine, Heidelberg University, 69120, Heidelberg, Germany.
Dustin SchillingInstitute for Computational Biomedicine, Bioquant, Faculty of Medicine, Heidelberg University and Heidelberg University Hospital, Im Neuenheimer Feld 130, 69120, Heidelberg, Germany.
Marc A SchneiderTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, Röntgenstraße 1, 69126, Heidelberg, Germany.
Nina Kunze-RohrbachCentre for Organismal Studies (COS), Metabolomics Core Technology Platform, Heidelberg University, Im Neuenheimer Feld 360, 69120, Heidelberg, Germany.
Thomas G P GrünewaldDivision of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Rüdiger HellCentre for Organismal Studies (COS), Metabolomics Core Technology Platform, Heidelberg University, Im Neuenheimer Feld 360, 69120, Heidelberg, Germany.
Julio Saez-RodriguezInstitute for Computational Biomedicine, Bioquant, Faculty of Medicine, Heidelberg University and Heidelberg University Hospital, Im Neuenheimer Feld 130, 69120, Heidelberg, Germany.
Wolfgang HuberGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstr. 1, 69117, Heidelberg, Germany.
Gernot PoschetCentre for Organismal Studies (COS), Metabolomics Core Technology Platform, Heidelberg University, Im Neuenheimer Feld 360, 69120, Heidelberg, Germany. gernot.poschet@cos.uni-heidelberg.de.
Jeroen KrijgsveldFaculty of Medicine, Heidelberg University, 69120, Heidelberg, Germany. j.krijgsveld@dkfz.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the interplay of the proteome and the metabolome helps to understand cellular regulation and response. To enable robust inferences from such multi-omics analyses, we introduced and evaluated a workflow for combined proteome and metabolome analysis starting from a single sample. Specifically, we integrated established and individually optimized protocols for metabolomic and proteomic profiling (EtOH/MTBE and autoSP3, respectively) into a unified workflow (termed MTBE-SP3), and took advantage of the fact that the protein residue of the metabolomic sample can be used as a direct input for proteome analysis. We particularly evaluated the performance of proteome analysis in MTBE-SP3, and demonstrated equivalence of proteome profiles irrespective of prior metabolite extraction. In addition, MTBE-SP3 combines the advantages of EtOH/MTBE and autoSP3 for semi-automated metabolite extraction and fully automated proteome sample preparation, respectively, thus advancing standardization and scalability for large-scale studies. We showed that MTBE-SP3 can be applied to various biological matrices (FFPE tissue, fresh-frozen tissue, plasma, serum and cells) to enable implementation in a variety of clinical settings. To demonstrate applicability, we applied MTBE-SP3 and autoSP3 to a lung adenocarcinoma cohort showing consistent proteomic alterations between tumour and non-tumour adjacent tissue independent of the method used. Integration with metabolomic data obtained from the same samples revealed mitochondrial dysfunction in tumour tissue through deregulation of OGDH, SDH family enzymes and PKM. In summary, MTBE-SP3 enables the facile and reliable parallel measurement of proteins and metabolites obtained from the same sample, benefiting from reduced sample variation and input amount. This workflow is particularly applicable for studies with limited sample availability and offers the potential to enhance the integration of metabolomic and proteomic datasets.

Identifiers

PMID38969985
PMCPMC11225228

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.